These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 38671389)
1. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer. Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389 [TBL] [Abstract][Full Text] [Related]
2. Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/β-catenin signaling. Kolegraff K; Nava P; Helms MN; Parkos CA; Nusrat A Mol Biol Cell; 2011 Apr; 22(8):1121-34. PubMed ID: 21325624 [TBL] [Abstract][Full Text] [Related]
3. Androgen downregulates desmocollin-2 in association with induction of mesenchymal transition of breast MDA-MB-453 cancer cells. Ahram M; Abdullah MS; Mustafa SA; Alsafadi DB; Battah AH Cytoskeleton (Hoboken); 2021 Aug; 78(8):391-399. PubMed ID: 35023302 [TBL] [Abstract][Full Text] [Related]
4. Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. Kamekura R; Kolegraff KN; Nava P; Hilgarth RS; Feng M; Parkos CA; Nusrat A Oncogene; 2014 Sep; 33(36):4531-6. PubMed ID: 24166502 [TBL] [Abstract][Full Text] [Related]
5. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Hütz K; Zeiler J; Sachs L; Ormanns S; Spindler V Mol Carcinog; 2017 Aug; 56(8):1884-1895. PubMed ID: 28277619 [TBL] [Abstract][Full Text] [Related]
6. TROP2 Down-regulated DSG2 to Promote Gastric Cancer Cell Invasion and Migration by EGFR/AKT and DSG2/PG/β-Catenin Pathways. Yang T; Jia L; Bian S; Chang X; Zhang Q; Tang Q; Zhu J; Yang Z; Feng Z Curr Cancer Drug Targets; 2022 Aug; 22(8):691-702. PubMed ID: 35392784 [TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway. Kong LY; Xue M; Zhang QC; Su CF Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945 [TBL] [Abstract][Full Text] [Related]
8. Desmoglein 2, but not desmocollin 2, protects intestinal epithelia from injury. Gross A; Pack LAP; Schacht GM; Kant S; Ungewiss H; Meir M; Schlegel N; Preisinger C; Boor P; Guldiken N; Krusche CA; Sellge G; Trautwein C; Waschke J; Heuser A; Leube RE; Strnad P Mucosal Immunol; 2018 Nov; 11(6):1630-1639. PubMed ID: 30115995 [TBL] [Abstract][Full Text] [Related]
9. Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling in oesophageal squamous cell carcinoma. Fang WK; Liao LD; Li LY; Xie YM; Xu XE; Zhao WJ; Wu JY; Zhu MX; Wu ZY; Du ZP; Wu BL; Xie D; Guo MZ; Xu LY; Li EM J Pathol; 2013 Oct; 231(2):257-70. PubMed ID: 23836524 [TBL] [Abstract][Full Text] [Related]
10. Significance of desmoglein-2 on cell malignant behaviors via mediating MAPK signaling in cervical cancer. Zhou BX; Li Y Kaohsiung J Med Sci; 2020 May; 36(5):336-343. PubMed ID: 31930774 [TBL] [Abstract][Full Text] [Related]
11. Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter study. Bhuiyan ZA; Jongbloed JD; van der Smagt J; Lombardi PM; Wiesfeld AC; Nelen M; Schouten M; Jongbloed R; Cox MG; van Wolferen M; Rodriguez LM; van Gelder IC; Bikker H; Suurmeijer AJ; van den Berg MP; Mannens MM; Hauer RN; Wilde AA; van Tintelen JP Circ Cardiovasc Genet; 2009 Oct; 2(5):418-27. PubMed ID: 20031616 [TBL] [Abstract][Full Text] [Related]
12. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway. Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829 [TBL] [Abstract][Full Text] [Related]
14. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171 [TBL] [Abstract][Full Text] [Related]
15. Regulation of intestinal epithelial intercellular adhesion and barrier function by desmosomal cadherin desmocollin-2. Raya-Sandino A; Luissint AC; Kusters DHM; Narayanan V; Flemming S; Garcia-Hernandez V; Godsel LM; Green KJ; Hagen SJ; Conway DE; Parkos CA; Nusrat A Mol Biol Cell; 2021 Apr; 32(8):753-768. PubMed ID: 33596089 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway. Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203 [TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer. Wang H; Wu D; Cai L; Li X; Zhang Z; Chen S J Cell Mol Med; 2020 Jun; 24(12):6869-6882. PubMed ID: 32394588 [TBL] [Abstract][Full Text] [Related]
18. Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling. Shin WS; Oh SW; Park HN; Kim JH; Lee ST Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569547 [TBL] [Abstract][Full Text] [Related]
19. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling. Liu L; Yu D; Shi H; Li J; Meng L Pharmazie; 2017 Oct; 72(10):599-603. PubMed ID: 29441885 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A. Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]